CRITERIUM, Inc. Global CRO Announces New Acquisition – Former Aptium Oncology Cancer Consortium Finds a New Home

Share Article

Criterium, Inc., a Global CRO, is proud to include CORE Science Solutions (CSS), an academic cancer research consortia in its family of companies. Well-known institutions and investigators are actively collaborating as part of the CSS Consortia. You can find them on CSS websites at: http://www.agicc.org and http://www.ammyc.org

News Image

Criterium, Inc., Global CRO acquires CSS
an Academic Cancer Research Corsortia

The vision of the CSS Consortia is to nothing less than to “Change the Way Cancer is Managed,” says McKinley.

Criterium, Inc., a full-service, global CRO, is pleased to announce the acquisition of the former Aptium Oncology’s CORE Science Solutions (CSS) Cancer Consortium Groups consisting of AGICC and AMyC as the newest members of Criterium’s Pharma services companies.

John Hudak, President and Founder of Criterium views this as an unusual and exciting growth prospect for an expanding CRO. “The opportunity here to serve Cancer Research at this level is phenomenal for us,” he said. “CORE Science Solutions (CSS) is delighted to be tapped by Criterium Inc. to become a part of their family,” stated Director of Clinical Research, Marti McKinley.

The CSS Consortia for GI Cancers and Myeloma has a truly unique and innovative research model that combines full service CRO capabilities with the expertise and knowledge of top oncology research investigators such as Brian G.M. Durie, MD, who emphasized that “AMyC fills a critical need for pharmaceutical sponsors, providing an unparalleled level of strategic, scientific, and operational expertise in a timely manner.” The CSS Consortia’s focus is on Phase I & II Clinical Trials where they provide pharmaceutical sponsors with extensive, cutting-edge therapeutic expertise and virtual advisory board services for oncology product development programs. Their ability to assist sponsors in capitalizing on current trends in oncology drug development (such as translational research and targeted therapy) offers the potential to facilitate the difficult go/no-go decisions required early on in the development and evaluation of a compound.

The vision of the CSS Consortia is nothing less than to “change the way cancer is managed,” says McKinley. Important and well-known institutions and investigators are actively collaborating as part of the CSS Consortia. You can find them on the CSS Consortia’s websites at: http://www.agicc.org and http://www.ammyc.org

ABOUT CRITERIUM
Criterium, Inc. is a full-service, global CRO (contract research organization) that offers a unique mix of high-quality clinical research services and communication processes for the biopharmaceutical, pharmaceutical, and medical device industries to manage trials from initial planning to approval. Founded in 1991, Criterium’s services are customized to fit each client’s specific needs, providing a seamless flow of data and information from the investigative site through Criterium and back to the sponsor — 24/7, in real-time.

Criterium’s experienced team manages and implements clinical trials using technology-based solutions. Dedicated clinical professionals are committed to providing personal service and to forming strong and productive relationships with clients. Criterium’s well-established staff are trained according to ICH GCP guidelines.

Corporate headquarters are located in Saratoga Springs, New York with offices in Florida, California, South Africa, India, and Canada, and representatives in-country in The Netherlands, Israel, and Russia. This multi-national approach enables Criterium to provide time- and cost-efficient study management and monitoring to all our clients. To learn more about Criterium, visit the website http://www.criteriuminc.com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ronny Schnel, Exec Dir Bus Dev

Marti McKinley, Director Clinical Research
Visit website

Media